Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
BMS Files Hypertrophic Cardiomyopathy Drug in Japan
Bristol Myers Squibb said on July 17 that it has submitted a new drug application in Japan for mavacamten, known with the brand name of Camzyos overseas, for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is an allosteric and…
To read the full story
Related Article
BUSINESS
- Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
- Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
- Eisai Snares Japan Commercial Rights to Henlius’ PD-1 Inhibitor
February 6, 2026
- Takeda Rolls Out 31-Foot Containers for Drug Transport
February 6, 2026
- Okajima to Take Helm of Asahi Kasei Pharma in April
February 6, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…